Y Intercept Hong Kong Ltd Sells 11,812 Shares of TransMedics Group, Inc. $TMDX

Y Intercept Hong Kong Ltd lowered its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 32.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,380 shares of the company’s stock after selling 11,812 shares during the quarter. Y Intercept Hong Kong Ltd owned 0.07% of TransMedics Group worth $2,735,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMDX. Envestnet Portfolio Solutions Inc. grew its position in TransMedics Group by 7.8% during the 3rd quarter. Envestnet Portfolio Solutions Inc. now owns 4,495 shares of the company’s stock worth $504,000 after purchasing an additional 324 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in TransMedics Group by 49.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 2,602 shares of the company’s stock worth $300,000 after acquiring an additional 865 shares during the period. Inspire Advisors LLC purchased a new position in TransMedics Group during the third quarter valued at approximately $603,000. Yorktown Management & Research Co Inc acquired a new position in TransMedics Group in the third quarter valued at approximately $393,000. Finally, Amalgamated Bank grew its stake in shares of TransMedics Group by 2.5% during the 3rd quarter. Amalgamated Bank now owns 9,827 shares of the company’s stock worth $1,103,000 after purchasing an additional 241 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Down 1.5%

Shares of NASDAQ TMDX traded down $2.09 during mid-day trading on Wednesday, reaching $136.40. The company had a trading volume of 31,878 shares, compared to its average volume of 699,128. The stock has a market capitalization of $4.66 billion, a PE ratio of 55.07 and a beta of 2.03. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. TransMedics Group, Inc. has a twelve month low of $62.07 and a twelve month high of $156.00. The stock’s 50 day moving average is $133.78 and its 200-day moving average is $123.25.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The firm had revenue of $143.82 million for the quarter, compared to the consensus estimate of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The firm’s revenue was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.12 earnings per share. As a group, equities analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director David Weill sold 5,000 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the transaction, the director directly owned 12,134 shares in the company, valued at approximately $1,682,257.76. This trade represents a 29.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 8,920 shares of company stock worth $1,257,310. 7.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

TMDX has been the topic of a number of research analyst reports. Morgan Stanley boosted their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Jefferies Financial Group began coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price target on the stock. Zacks Research cut TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Canaccord Genuity Group raised their price target on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.25.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.